RATIONALE Pravastatin has emerged for prevention and treatment of preeclampsia; no reports are available on pravastatin and HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome. PATIENT CONCERNS The first pregnancy necessitated termination of pregnancy at gestational age (GA) 20+5 for HELLP. Intrauterine fetal death at GA 22+5 occurred in the second pregnancy, whilst on tempor...

The HELLP syndrome is a serious complication in pregnancy characterized by haemolysis, elevated liver enzymes and low platelet count occurring in 0.5 to 0.9% of all pregnancies and in 10–20% of cases with severe preeclampsia. Aim: The objective of the present prospective study is on incidence, diagnosis, and its variable presentations of HELLP syndrome in preeclampsia, eclampsia to analyze the ...

BACKGROUND AND OBJECTIVES Among the array of microangiopathies that may occur during pregnancy, HELLP syndrome and thrombotic thrombocytopenic purpura (TTP) produce similar laboratory findings (hemolytic anemia and thrombocytopenia), although neurological symptoms prevail in TTP and abnormal liver function in HELLP syndrome. It is clinically important to distinguish the two entities given that ...

OBJECTIVE HELLP syndrome is a severe form of preeclampsia, characterized by hemolysis (H), elevated liver enzymes (EL), and low platelets (LP), whose pathogenesis is unclear. Autoimmunity is thought to play an important role. After the observation of development of type 1 diabetes in a patient with HELLP syndrome, we assumed a possible disease association based on autoimmune reactions. RESEAR...

Introduction: L'objectif de ce travail etait d'étudier et comparer les paramètres épidémiologiques, cliniques, paracliniques et évolutifs des patientes présentant un HELLP syndrome complet et incomplet. (Hemolysis, Elevated Liver enzymes, Low Platelets count). Méthodes: Une enquête rétrospective sur la période du 1er janvier 2005 au 31octobre 2008 et incluant tous les cas de HELLP syndrome coll...

Background: Objective of current study was to determine the incidence of HELLP syndrome in patients with eclampsia and its impact on maternal and perinatal outcome. Methods: The prospective study was conducted in the department of obstetrics and gynaecology, Burdwan medical college, Burdwan on 727 eclamptic mothers, admitted from January 2012 to December 2013. Clinical data and detailed investi...

Plasma exchange therapy has been successfully used in selected patients with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome who have organ failure or refractory to treatment. There is no prospective study regarding plasma exchange and its effect in HELLP syndrome. The aim of this study was to investigate the effects of early postpartum use of plasma exchange in patients w...

Recent findings have revealed the role of prion-like mechanisms in the control of host defense and programmed cell death cascades. In fungi, HET-S, a cell death-inducing protein containing a HeLo pore-forming domain, is activated through amyloid templating by a Nod-like receptor (NLR). Here we characterize the HELLP protein behaving analogously to HET-S and bearing a new type of N-terminal cell...

HELLP occurs in 0.5%-0.9% of all pregnancies. About 30% of the cases happen within 48 hours after delivery. Women with postpartum HELLP syndrome have significantly higher incidences of complications. Because of the absence of classical signs of preeclampsia, it can confuse physicians and lead to delay in diagnosis. Therefore, it is associated with serious maternal morbidity. We present two case...